ER · CARDIO · WEEKLY / 本週原始訊號 / L3 · CrossRef 期刊
SOURCES · JOURNALS

L3 · CrossRef 期刊

10 本 ECG / 心臟學期刊——Heart Rhythm / JACC-EP / Circulation-AE / J Electrocardiology / Annals EM / Resuscitation / Europace / JACC / EHJ / JAMA Cardiology。

59 筆 · cache 更新 2026-04-29T23:09:22+08:00
Circulation-AE

First-in-Human Clinical Experience with Focal Pulsed Field and Radiofrequency Dual-Modality Ablation for Treatment Refractory Left Ventricular Summit PVCs

Results: Six consecutive patients (4 male, mean age 53.8±15 years) with symptomatic LVS PVCs and a prior failed RF ablation (range 1-2) were prospectively enrolled. Background: Radiofrequency (RF) ablation of premature ventricular complexes (PVCs) originating from the left ventricular summit (LVS) may be unsuccessful, highlighting the need for alternative approaches.

2026-04-24 Patil S, Liu X, Siontis K, Prasitlumkum N DOI 10.1161/circep.126.014942 premature ventricularPVCECG
Circulation-AE

Variability in Tissue Interface Temperature During Pulse Field Atrial Ablation: Implications for Real-Time Contact Assessment

Univariate analysis showed peak temperature was positively associated with previous lesion temperature ( r =0.65 [95% CI, 0.63–0.67]; P <0.001) and had weak associations with time between lesions ( r =−0.15 [−0.19 to −0.11]; P <0.001) and percentage impedance drop ( r =0.20 [95% CI, 0.16–0.23]; P <0.001).

2026-04-20 Power J, Watanabe K, Shinohara M, Yu F DOI 10.1161/circep.125.014310 atrial fibrillation
European Heart J

Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: the STOPSTORM.eu study

Median follow-up was 19 months. Among 107 evaluable patients with ≥6-month follow-up, the median VT episode burden was reduced by 80% after STAR. The primary efficacy endpoint was the change in sustained VT episode burden comparing the 6 months before versus the 6 months after STAR.

2026-04-20 van der Pol L, Tomasik B, Hoeksema W, Mandija S DOI 10.1093/eurheartj/ehag338 arrhythmiaventricular tachycardiaVTtachycardiaICD
European Heart J

Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial

Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60–6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71–1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17–2.63), 6MWD, and SF-36 scores, also showed no significant differences.

2026-04-16 Sanders P, Ariyaratnam J, Stiles M, Puvrez A DOI 10.1093/eurheartj/ehag206 atrial fibrillationAFCRT